DelveInsight’s, “Cholangiocarcinoma Pipeline Insight 2024” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Cholangiocarcinoma pipeline landscape. It covers the Cholangiocarcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cholangiocarcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Request a sample and discover the recent advances in Cholangiocarcinoma Treatment Drugs @ Cholangiocarcinoma Pipeline Outlook

 

Key Takeaways from the Cholangiocarcinoma Pipeline Report

• In October 2024:- Servier Bio-Innovation LLC- A Phase 1/2, Safety Lead-in and Dose Expansion, Open-label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Activity of Ivosidenib in Combination With Nivolumab and Ipilimumab in Previously Treated Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
• In October 2024:- Taiho Oncology Inc.- This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements.
• In October 2024:- Seagen Inc.- A Phase 1b/2 Dose Escalation and Expansion Study of Tucatinib in Combination With Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers. The participants in this trial have HER2-positive (HER2+) cancer in their gut, stomach, intestines, or gallbladder (gastrointestinal cancer).
• DelveInsight’s Cholangiocarcinoma pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Cholangiocarcinoma treatment.
• The leading companies working in the Cholangiocarcinoma Market include Merck Sharp & dohme, Eisai, RedHill Biopharma Limited, TransThera Science, Kinnate Biopharma, Taiho Oncology, Bristol-Myers Squibb, AstraZeneca, Jiangsu Hengrui Medicine Co. Ltd., GlaxoSmithKline, Beijing InnoCare Pharma, Genoscience, 3D Medicines, Innovent Biologics (Suzhou) Co. Ltd., QED Therapeutics, Hutchison MediPharma, TriSalus Life Sciences, Relay Therapeutics, Eli Lilly and Company, Medivir, Boehringer Ingelheim, Compass Therapeutics, Intensity Therapeutics, Sirnaomics, Wellmarker Bio, and others.
• Promising Cholangiocarcinoma Pipeline Therapies in the various stages of development include Tinengotinib 8 mg, Ivosidenib, CX-4945, Cisplatin, Gemcitabine, E7090, Pemigatinib, and others. 

  

Find out more about Cholangiocarcinoma Therapeutics Assessment @ Cholangiocarcinoma Preclinical and Discovery Stage Products

 

Cholangiocarcinoma Emerging Drugs Profile

• Pembrolizumab: Merck Sharp & dohme
• E7090: Eisai
• ABC294640: RedHill Biopharma Limited
• TT-00420: TransThera Science
• KIN-3248: Kinnate Biopharma

 

Cholangiocarcinoma Pipeline Therapeutics Assessment

There are approx. 55+ key companies which are developing the Cholangiocarcinoma therapies. The Cholangiocarcinoma companies which have their Cholangiocarcinoma drug candidates in the most advanced stage, i.e. Phase III include, Merck Sharp & dohme.

 

Learn more about the emerging Cholangiocarcinoma Pipeline Therapies @ Cholangiocarcinoma Clinical Trials Assessment

 

DelveInsight’s Cholangiocarcinoma pipeline report covers around 60+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Cholangiocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

 

Cholangiocarcinoma Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

 

Dive deep into rich insights for new drugs for Cholangiocarcinoma Treatment, Visit @ Cholangiocarcinoma Market Drivers and Barriers, and Future Perspective

 

Scope of the Cholangiocarcinoma Pipeline Report

• Coverage- Global
• Cholangiocarcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Cholangiocarcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Cholangiocarcinoma Companies- Merck Sharp & dohme, Eisai, RedHill Biopharma Limited, TransThera Science, Kinnate Biopharma, Taiho Oncology, Bristol-Myers Squibb, AstraZeneca, Jiangsu Hengrui Medicine Co. Ltd., GlaxoSmithKline, Beijing InnoCare Pharma, Genoscience, 3D Medicines, Innovent Biologics (Suzhou) Co. Ltd., QED Therapeutics, Hutchison MediPharma, TriSalus Life Sciences, Relay Therapeutics, Eli Lilly and Company, Medivir, Boehringer Ingelheim, Compass Therapeutics, Intensity Therapeutics, Sirnaomics, Wellmarker Bio, and others.
• Cholangiocarcinoma Pipeline Therapies- Tinengotinib 8 mg, Ivosidenib, CX-4945, Cisplatin, Gemcitabine, E7090, Pemigatinib, and others.

 

For further information on the Cholangiocarcinoma Pipeline therapeutics, reach out to Cholangiocarcinoma Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Cholangiocarcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Cholangiocarcinoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Pembrolizumab: Merck Sharp & dohme
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. E7090: Eisai
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. KIN-3248: Kinnate Biopharma
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Cholangiocarcinoma Key Companies
21. Cholangiocarcinoma Key Products
22. Cholangiocarcinoma- Unmet Needs
23. Cholangiocarcinoma- Market Drivers and Barriers
24. Cholangiocarcinoma- Future Perspectives and Conclusion
25. Cholangiocarcinoma Analyst Views
26. Cholangiocarcinoma Key Companies
27. Appendix 

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/